Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.53 |
| ▸ | DPP4 | P27487 | 10/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.40 |
| ▸ | CCR1 | P32246 | 2/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | GPR6 | P46095 | 3/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4113701 | 1.00 | CNR2 (0.53) | CNR2DPP4DPP7CCR1DPP9 | |
| SCHEMBL4113698 | 1.00 | CNR2 (0.53) | CNR2DPP4DPP7CCR1DPP9 | |
| SCHEMBL4127101 | 0.95 | CNR2 (0.54) | CNR2DPP4DPP7CCR1RORC | |
| SCHEMBL4127106 | 0.95 | CNR2 (0.54) | CNR2DPP4DPP7CCR1RORC | |
| SCHEMBL4109367 | 0.93 | CNR2 (0.52) | CNR2DPP4DPP7CCR1RORC | |
| SCHEMBL4117125 | 0.93 | CNR2 (0.52) | CNR2DPP4DPP7CCR1RORC | |
| SCHEMBL4109364 | 0.93 | CNR2 (0.52) | CNR2DPP4DPP7CCR1RORC | |
| SCHEMBL4108146 | 0.93 | CNR2 (0.52) | CNR2DPP4DPP7CCR1RORC | |
| SCHEMBL4109814 | 0.92 | CNR2 (0.53) | CNR2CCR1RORCGPR6 | |
| SCHEMBL4109810 | 0.92 | CNR2 (0.53) | CNR2CCR1RORCGPR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431565-B2 | Substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431565-B2 | Substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431565-B2 | Substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CNR1, CNR2, TRPV1 | CNR2 2/4885DPP4 4359/4885DPP7 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.